Video

Dr. Popat on the Clinical Implications of the Final Results of the ALTA-1L Trial in ALK+ NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.

Sanjay Popat, BSc, MBBS, FRCP, PhD, professor, consultant thoracic medical oncologist, The Royal Marsden, honorary clinical senior lecturer, Molecular Genetics and Genomics Group, National Heart and Lung Institute, Imperial College London, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial (NCT02737501) in ALK-positive non–small cell lung cancer (NSCLC).

During the 2021 ESMO Congress, the final results of the ALTA-1L trial were presented virtually. The findings demonstrated consistent efficacy and safety with brigatinib (Alunbrig) vs crizotinib (Xalkori) in patients with ALK-positive NSCLC as reported in previous interim analyses. Brigatinib induced a 52% reduction in the risk of disease progression or death compared with crizotinib in this patient population, Popat says. Although overall survival data are maturing, a similar OS was observed in the brigatinib and crizotinib arms. 

Additionally, high intracranial efficacy continued to be observed with brigatinib, which reduced the risk of intracranial progression by 56% in all patients and 71% in patients with baseline brain metastases vs crizotinib, Popat says.

Finally, treatment with brigatinib was associated with improved health-related quality of life compared with crizotinib, Popat concludes.

Sponsorship provided by Takeda/Content Developed Independently by OncLive

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.